Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$166.31 USD

166.31
846,374

+7.95 (5.02%)

Updated May 2, 2024 04:00 PM ET

After-Market: $166.43 +0.05 (0.03%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Repligen (RGEN) Stock?

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

Smart Beta ETF report for JSMD

Why Is CRISPR Therapeutics AG (CRSP) Up 1.8% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Repligen (RGEN) Up 2.7% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 8.47% and 0.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates

Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 17.24% and 0.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?

Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.

HZNP vs. RGEN: Which Stock Is the Better Value Option?

HZNP vs. RGEN: Which Stock Is the Better Value Option?

Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIIB or RGEN: Which Is the Better Value Stock Right Now?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

BIIB vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Repligen (RGEN) Q3 Earnings and Revenues Top Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 13.24% and 4.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?

Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.